Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Rush University Medical Center
mi
from
Chicago, IL
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Duke Univ Med Ctr
mi
from
Durham, NC
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
UPMC Cancer Center
mi
from
Pittsburgh, PA
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated:  12/15/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated:  12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
A Phase II Study of Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated:  12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
A Phase II Study of Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated: 12/15/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand
A Prospective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/21/2015
Intermountain Health Care
mi
from
Salt Lake City, UT
Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand
A Prospective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/21/2015
Intermountain Health Care
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand
A Prospective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/21/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand
A Prospective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/21/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated:  12/21/2015
University of Chicago
mi
from
Chicago, IL
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated: 12/21/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated:  12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated: 12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated:  12/21/2015
Royal Prince Alfred Hospital
mi
from
Sydney,
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated: 12/21/2015
Royal Prince Alfred Hospital
mi
from
Sydney,
Click here to add this to my saved trials
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated:  12/22/2015
St. Mary's Duluth Clinic Health System
mi
from
Duluth, MN
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated: 12/22/2015
St. Mary's Duluth Clinic Health System
mi
from
Duluth, MN
Click here to add this to my saved trials
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated:  12/22/2015
Tom Baker Cancer Center - Calgary
mi
from
Calgary,
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated: 12/22/2015
Tom Baker Cancer Center - Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Juravinski Cancer Centre at Hamilton Health Sciences
mi
from
Hamilton,
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Juravinski Cancer Centre at Hamilton Health Sciences
mi
from
Hamilton,
Click here to add this to my saved trials
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated:  1/8/2016
National Cacner Institue
mi
from
Bethesda, MD
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated: 1/8/2016
National Cacner Institue
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic research site
mi
from
Fresno, CA
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic research site
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic Research Site
mi
from
San Luis Obispo, CA
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic Research Site
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic Research Site
mi
from
Fairway, KA
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic Research Site
mi
from
Fairway, KA
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic Research Site
mi
from
Boston, MA
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic Research Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic Research Site
mi
from
Durham, NC
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic Research Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
Tetralogic research site
mi
from
Philadelphia, PA
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
Tetralogic research site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
Tetralogic research site
mi
from
Philadelphia, PA
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
Tetralogic research site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic Research Site
mi
from
Nashville, TN
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic Research Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  1/13/2016
TetraLogic Research Facility
mi
from
Dallas, TX
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 1/13/2016
TetraLogic Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
WISER After Ovarian Cancer - Exercise Pilot Study
WISER After Ovarian Cancer - Exercise Pilot Study
Status: Enrolling
Updated:  1/14/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
WISER After Ovarian Cancer - Exercise Pilot Study
WISER After Ovarian Cancer - Exercise Pilot Study
Status: Enrolling
Updated: 1/14/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Ovarian Cancer Early Detection Screening Program
Status: Enrolling
Updated:  1/15/2016
Marsha Rivkin Center for Ovarian Cancer Research
mi
from
Seattle, WA
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Ovarian Cancer Early Detection Screening Program
Status: Enrolling
Updated: 1/15/2016
Marsha Rivkin Center for Ovarian Cancer Research
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Site Reference ID/Investigator# 117337
mi
from
Groningen,
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Site Reference ID/Investigator# 117337
mi
from
Groningen,
Click here to add this to my saved trials
Tivozanib As Maintenance Therapy In GYN
A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  1/27/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Tivozanib As Maintenance Therapy In GYN
A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 1/27/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Prevention of Ovarian Cancer in Women Participating in Mammography
Prevention of Ovarian Cancer in Women Participating in Mammography
Status: Enrolling
Updated:  1/27/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Prevention of Ovarian Cancer in Women Participating in Mammography
Prevention of Ovarian Cancer in Women Participating in Mammography
Status: Enrolling
Updated: 1/27/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated:  1/31/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated: 1/31/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission
Status: Enrolling
Updated:  2/1/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission
Status: Enrolling
Updated: 2/1/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Analyzing the Composition of Tears to Identify Cancer
ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)
Status: Enrolling
Updated:  2/2/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Analyzing the Composition of Tears to Identify Cancer
ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)
Status: Enrolling
Updated: 2/2/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated:  2/3/2016
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated:  2/3/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated:  2/3/2016
Dana-Farber Cancer Institue
mi
from
Boston, MA
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Dana-Farber Cancer Institue
mi
from
Boston, MA
Click here to add this to my saved trials
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated:  2/4/2016
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated: 2/4/2016
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated:  2/4/2016
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated: 2/4/2016
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated:  2/4/2016
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated: 2/4/2016
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated:  2/4/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Status: Enrolling
Updated: 2/4/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials